Rodman David's Insider Trades & SAST Disclosures
Rodman David's most recent trade in Mineralys Therapeutics Inc was a trade of 11,366 Common Stock done at an average price of $15.3 . Disclosure was reported to the exchange on May 14, 2025.
Add Superstar Alert
Share
Note
This is a custom search result for pattern Rodman David.To see full superstar portfolios of large investors like Warren Buffet, Elon Musk and others, click here.
Advanced/Help
"Balanced Fund": Use this format with quotation marks to find the exact phrase. The output matches
"Balanced Fund"
but not "Balanced Growth Fund"
Balanced Fund: Use this format without quotation marks to search for all funds related to the term
"Balanced Fund" The results may include
"Balanced Income Fund", "Balanced Growth Fund" and any fund name containing "Balanced Fund".
| Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
|---|---|---|---|---|---|---|---|---|---|---|
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.29 per share. | 14 May 2025 | 11,366 | 106,669 | - | 15.3 | 173,774 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 May 2025 | 6,349 | 118,035 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 May 2025 | 6,349 | 101,577 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 14.83 per share. | 14 Apr 2025 | 8,400 | 111,686 | - | 14.8 | 124,572 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 14 Apr 2025 | 6,348 | 107,926 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 14 Apr 2025 | 6,348 | 123,052 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.69 per share. | 14 Apr 2025 | 2,966 | 120,086 | - | 13.7 | 40,613 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 01 Apr 2025 | 30,574 | 141,901 | - | 15.0 | 458,543 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.77 per share. | 01 Apr 2025 | 22,406 | 116,704 | - | 16.8 | 375,749 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 16.02 per share. | 01 Apr 2025 | 2,791 | 139,110 | - | 16.0 | 44,717 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 01 Apr 2025 | 1,606 | 114,274 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 01 Apr 2025 | 1,606 | 172,475 | - | 1.1 | 1,734 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Mar 2025 | 6,349 | 115,880 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Mar 2025 | 6,349 | 170,869 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2025 | 170,000 | 170,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Feb 2025 | 6,348 | 164,520 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2025 | 6,348 | 122,229 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 13 Jan 2025 | 6,349 | 158,172 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 6,349 | 128,577 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 13 Jan 2025 | 5,018 | 151,823 | - | 0.5 | 2,710 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 Jan 2025 | 5,018 | 0 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2024 | 5,017 | 5,018 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Rodman David | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Dec 2024 | 5,017 | 146,008 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 5,026 | 134,926 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 11 Nov 2024 | 5,026 | 140,991 | - | 15.0 | 75,398 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Nov 2024 | 5,026 | 146,017 | - | 1.1 | 5,428 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Nov 2024 | 5,017 | 140,991 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Nov 2024 | 5,017 | 10,035 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.03 per share. | 06 Nov 2024 | 25,482 | 135,974 | - | 15.0 | 383,066 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 06 Nov 2024 | 25,482 | 161,456 | - | 1.1 | 27,521 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 06 Nov 2024 | 25,482 | 139,952 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 5,352 | 165,434 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Oct 2024 | 5,352 | 135,974 | - | 1.1 | 5,780 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Oct 2024 | 5,017 | 130,622 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Oct 2024 | 5,017 | 15,052 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 6,349 | 170,786 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Sep 2024 | 6,349 | 125,605 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Sep 2024 | 5,018 | 119,256 | - | 0.5 | 2,710 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Sep 2024 | 5,018 | 20,069 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 6,348 | 177,135 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Aug 2024 | 6,348 | 114,238 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Aug 2024 | 5,017 | 25,087 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 12 Aug 2024 | 5,017 | 107,890 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 16 Jul 2024 | 525 | 183,483 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 16 Jul 2024 | 525 | 102,873 | - | 15.0 | 7,876 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 16 Jul 2024 | 525 | 103,398 | - | 1.1 | 567 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Jul 2024 | 6,349 | 102,873 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 6,349 | 184,008 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Jul 2024 | 5,017 | 96,524 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jul 2024 | 5,017 | 30,104 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Jun 2024 | 6,349 | 89,729 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2024 | 6,349 | 190,357 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jun 2024 | 5,017 | 35,121 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Jun 2024 | 5,017 | 83,380 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 13 May 2024 | 6,348 | 78,363 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 6,348 | 196,706 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 13 May 2024 | 5,018 | 40,138 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 13 May 2024 | 5,018 | 72,015 | - | 0.5 | 2,710 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 09 May 2024 | 100 | 67,097 | - | 1.1 | 108 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 09 May 2024 | 100 | 203,054 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 15.00 per share. | 09 May 2024 | 100 | 66,997 | - | 15 | 1,500 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2024 | 6,349 | 203,154 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Apr 2024 | 6,349 | 66,997 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Apr 2024 | 5,017 | 60,648 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Apr 2024 | 5,017 | 45,156 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Mar 2024 | 6,348 | 55,631 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 6,348 | 209,503 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Mar 2024 | 5,017 | 50,173 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Mar 2024 | 5,017 | 49,283 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 13 Feb 2024 | 200,000 | 200,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 12 Feb 2024 | 6,349 | 44,266 | - | 1.1 | 6,857 | Common Stock |
| Mineralys Therapeutics Inc | Rodman David | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 6,349 | 215,851 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Rodman David | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 12 Feb 2024 | 5,017 | 37,917 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 12 Feb 2024 | 5,017 | 55,190 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | Rodman David | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 11 Jan 2024 | 6,348 | 32,900 | - | 1.1 | 6,856 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2024 | 6,348 | 222,200 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Jan 2024 | 5,017 | 60,207 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Jan 2024 | 5,017 | 26,552 | - | 0.5 | 2,709 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 11 Dec 2023 | 5,018 | 20,069 | - | 0.5 | 2,710 | Common Stock |
| Mineralys Therapeutics Inc | Rodman David | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 11 Dec 2023 | 5,018 | 65,224 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 80,909 | 85,293 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.81 per share. | 10 Aug 2023 | 80,909 | 0 | - | 12.8 | 1,036,444 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 10 Aug 2023 | 80,909 | 80,909 | - | 0.5 | 43,691 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 12.81 per share. | 10 Aug 2023 | 76,182 | 0 | - | 12.8 | 975,891 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 1.08 per share. | 10 Aug 2023 | 76,182 | 76,182 | - | 1.1 | 82,277 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 76,182 | 228,548 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.00 per share. | 10 Aug 2023 | 74,625 | 166,202 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Sale of securities on an exchange or to another person at price $ 13.16 per share. | 10 Aug 2023 | 74,625 | 0 | - | 13.2 | 982,065 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Exercise or conversion of derivative security received from the company (such as an option) at price $ 0.54 per share. | 10 Aug 2023 | 74,625 | 74,625 | - | 0.5 | 40,298 | Common Stock |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 17 Mar 2023 | 20,000 | 20,000 | - | - | Stock Option | |
| Mineralys Therapeutics Inc | David Rodman | Chief Medical Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 09 Feb 2023 | 104,186 | 104,186 | - | - | Stock Option |
*All Values are in $ Million
Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures
Security Type: Share/ Warrants / Convertible Debentures
Data as reported to USA Exchanges